Talacotuzumab

N/A

Report date: 2022/07/19 16:22:54

Base Information

Drug NameTalacotuzumab
Drug Alias NameCSL-362IL-13 MAb-CSLJNJ-56022473CSL-362-AMLJNJ-473
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionInterleukin-3 receptor subunit alpha inhibitorsNatural killer cells stimulants
TargetsInterleukin-3 receptor subunit alpha
Therapy Area/IndicationsMyelodysplastic SyndromesLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesSweden +[16] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesCsl Ltd
China Registration ClassN/A

Develop Information

Active CompaniesJanssen Research & Development Llc
Inactive CompaniesGwt-Tud GmbhCsl Ltd
Active IndicationsMyelodysplastic Syndromes
Inactive IndicationsLeukemia, Myeloid, Acute

Other Information

ATC CodeN/A
Related LinksN/A